2 Rising Biotechs That Could Become the Next Novo Nordisk

With shares of Novo Nordisk (NYSE: NVO) skyrocketing by more than 200% over the last three years thanks to the outrageous success of its type 2 diabetes drug called Ozempic, investors are eager to determine what other companies in biopharma might be capable of following the same trajectory.But, as wise investors know, the next success stories are unlikely to be created with the exact same strategies as today's winners. That means looking for potential in a slightly different market than the one Novo Nordisk ...